M
Michele Dal Bo
Publications - 81
Citations - 1751
Michele Dal Bo is an academic researcher. The author has contributed to research in topics: Chronic lymphocytic leukemia & Leukemia. The author has an hindex of 22, co-authored 73 publications receiving 1418 citations.
Papers
More filters
Journal ArticleDOI
CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.
Antonella Zucchetto,Dania Benedetti,Claudio Tripodo,Riccardo Bomben,Michele Dal Bo,Daniela Marconi,Fleur Bossi,Debora Lorenzon,Massimo Degan,Francesca Rossi,Davide Rossi,Pietro Bulian,Vito Franco,Giovanni Del Poeta,Silvia Deaglio,Gianluca Gaidano,Francesco Tedesco,Fabio Malavasi,Valter Gattei +18 more
TL;DR: CD38 and CD49d can be thought of as parts of a consecutive chain of events ultimately leading to improved survival of CLL cells.
Journal ArticleDOI
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study.
Riccardo Bomben,Michele Dal Bo,Daniela Capello,Francesco Forconi,Rossana Maffei,Luca Laurenti,Davide Rossi,Maria Ilaria Del Principe,Antonella Zucchetto,Francesco Bertoni,Francesca Rossi,Pietro Bulian,Ilaria Cattarossi,Fiorella Ilariucci,Elisa Sozzi,Valeria Spina,Emanuele Zucca,Massimo Degan,Francesco Lauria,Giovanni Del Poeta,Dimitar G. Efremov,Roberto Marasca,Gianluca Gaidano,Valter Gattei +23 more
TL;DR: This analysis identified additional molecular and clinical features for CLL expressing stereotyped BCR, and identified 14 novel clusters, of which 11 had M IG rearrangements (M clusters) and predominantly (8/11) used IGHV3 subgroup genes.
Journal ArticleDOI
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia
Michele Dal Bo,Francesca Rossi,Davide Rossi,Clara Deambrogi,Francesco Bertoni,Ilaria Del Giudice,Giuseppe A. Palumbo,Mauro Nanni,Andrea Rinaldi,Ivo Kwee,Erika Tissino,Giorgia Corradini,Alessandro Gozzetti,Emanuele Cencini,Marco Ladetto,Angela Coletta,Fabrizio Luciano,Pietro Bulian,Gabriele Pozzato,Luca Laurenti,Francesco Forconi,Francesco Di Raimondo,Roberto Marasca,Giovanni Del Poeta,Gianluca Gaidano,Robin Foà,Anna Guarini,Valter Gattei +27 more
TL;DR: Results indicated that both percentage of deleted nuclei and presence of larger deletions involving the RB1 locus cooperated to refine the prognosis of del13q‐only cases, and CLL carrying 13q deletion with or without RB1 deletions collectively experienced shorter time‐to‐treatment.
Journal ArticleDOI
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study
Riccardo Bomben,Michele Dal Bo,Daniela Capello,Dania Benedetti,Daniela Marconi,Antonella Zucchetto,Francesco Forconi,Rossana Maffei,Emanuela M. Ghia,Luca Laurenti,Pietro Bulian,Maria Ilaria Del Principe,Giuseppe Palermo,Mia Thorsélius,Massimo Degan,Renato Campanini,Anna Guarini,Giovanni Del Poeta,Richard Rosenquist,Dimitar G. Efremov,Roberto Marasca,Robin Foà,Gianluca Gaidano,Valter Gattei +23 more
TL;DR: IGHV3-21 CLLs, including those with homHCDR3, had a peculiar global phenotype in part explaining their worse clinical outcome, and was more frequently encountered in Northern than Southern Europe.
Journal ArticleDOI
Analysis of IgVH gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery
Massimo Degan,Riccardo Bomben,Michele Dal Bo,Antonella Zucchetto,Paola Nanni,Maurizio Rupolo,Agostino Steffan,Vincenza Attadia,Pier Ferruccio Ballerini,Daniela Damiani,Carlo Pucillo,Giovanni Del Poeta,Alfonso Colombatti,Valter Gattei +13 more
TL;DR: Findings indicate the activation of a canonical SHM process in nsM and sM B‐CLLs and underscore the role of the antigen in defining the specific clinical and biological features of B‐ CLL.